FACT and found that the DUB module could cleave ubiquitin from H2B ( Fig. 4B and fig. S10 ). The rate of H2A/H2B-Ub deubiquitination was somewhat higher in the presence of FACT and is comparable to the rate at which the DUB module deubiquitinates nucleosomes (Fig. 4B) . FACT has no effect on the relative rate at which ubiquitin is cleaved from nucleosomes ( Fig. 4B) , thus ruling out a direct effect of FACT on intrinsic DUB module activity. Our results indicate that the SAGA DUB module can remove ubiquitin from either intact or disassembled nucleosomes and is therefore capable of acting at multiple points as RNA polymerase transcribes through a chromatin template.
We thank T. Formosa for the generous gift of purified FACT and S. Tan for the plasmid, pST55-16x601. We thank X. Zhang for assistance with protein purification, P. Lombardi for assistance with data collection, and D. Leahy for helpful discussions. Supported by grant GM-095822 from the National Institute of General Medical Sciences (C. In response to growth signals, mechanistic target of rapamycin complex 1 (mTORC1) stimulates anabolic processes underlying cell growth. We found that mTORC1 increases metabolic flux through the de novo purine synthesis pathway in various mouse and human cells, thereby influencing the nucleotide pool available for nucleic acid synthesis. mTORC1 had transcriptional effects on multiple enzymes contributing to purine synthesis, with expression of the mitochondrial tetrahydrofolate (mTHF) cycle enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) being closely associated with mTORC1 signaling in both normal and cancer cells. MTHFD2 expression and purine synthesis were stimulated by activating transcription factor 4 (ATF4), which was activated by mTORC1 independent of its canonical induction downstream of eukaryotic initiation factor 2a eIF2a phosphorylation. Thus, mTORC1 stimulates the mTHF cycle, which contributes one-carbon units to enhance production of purine nucleotides in response to growth signals.
T he mechanistic target of rapamycin complex 1 (mTORC1) kinase integrates diverse growth signals to control nutrient-consuming biosynthetic processes, such as protein and lipid synthesis (1). mTORC1 also acutely stimulates the de novo synthesis of pyrimidine nucleotides through a posttranslational mechanism leading to increased intracellular pools of pyrimidines available for RNA and DNA synthesis (2, 3). Whether mTORC1 also influences the synthesis of purine nucleotides is unknown. Purines are enzymatically assembled on a 5-phosphoribosyl pyrophosphate (PRPP) molecule derived from the pentose phosphate pathway, with carbon and nitrogen moieties donated by nonessential amino acids and one-carbon formyl units from the tetrahydrofolate (THF) cycle (Fig. 1A) .
To determine whether mTORC1 signaling affects de novo purine synthesis, we used targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure relative flux of stable isotope-labeled glutamine (amide-15 N), which is incorporated into the purine ring at two positions (Fig. 1A) . mTORC1 activation in response to both genetic [tuberous sclerosis complex 2 (Tsc2) null mouse embryo fibroblasts (MEFs)] and physiologic (insulin treatment of wild-type MEFs) stimuli resulted in increased amounts of doubly labeled 15 N-purine intermediates, and this labeling was attenuated in cells treated for 12 to 16 hours with the mTORC1 inhibitor rapamycin (Fig. 1, B and D, and fig. S1 , A to E). Unlike de novo pyrimidine synthesis, measured in the same metabolite extracts as the intermediate 15 Ncarbamoyl-aspartate (Fig. 1, C and E, and fig.  S1C) (2, 3) , a shorter 1-hour stimulation with *These authors contributed equally to this work. †Corresponding author. E-mail: bmanning@hsph.harvard.edu insulin or treatment with rapamycin failed to respectively increase or decrease purine flux (Fig. 1 , B and D, and fig. S1 , B and D). Similar results were obtained when flux from 13 C-glycine into purine intermediates was measured ( fig. S1F ). mTORC1 activation through either loss of Tsc2 or stimulation of cells with insulin increased flux through de novo purine synthesis into nucleic acids, as measured by 14 C-glycine incorporation into RNA and DNA, without pronounced effects on the incorporation of an exogenously provided purine base ( 3 H-adenine) (Fig. 1, F and G, and fig.  S1 , G to J). Likewise, rapamycin decreased 14 Cglycine flux into RNA in primary mouse hepatocytes and a panel of human cell lines (Fig. 1H) .
The delayed timing of the respective inhibitory and stimulatory effects of rapamycin and insulin on purine synthesis, relative to that of pyrimidine synthesis (2, 3) , suggested that mTORC1 might regulate this pathway through transcriptional mechanisms. Transcripts for specific enzymes within the purine pathway or essential supporting pathways, including the pentose phosphate pathway, serine synthesis, and the THF cycle (fig. S2A), were increased in Tsc2-deficient cells and sensitive to rapamycin treatment ( Fig. 2A and  fig. S2 , B to D). Among these genes, methylenetetrahydrofolate dehydrogenase 2 (Mthfd2), encoding an enzyme in the mTHF cycle, showed the greatest mTORC1-dependent induction. Of those genes altered by mTORC1 signaling, Mthfd2 was among the few that also showed corresponding changes in protein abundance, which were sensitive to both rapamycin and the mTOR kinase inhibitor Torin 1 (Fig. 2B ). MTHFD2 was reduced in cells treated with rapamycin for 8 hours ( fig.  S3A ), which was also sufficient to reduce de novo purine synthesis in these cells (Fig. 1F) .
Expression of MTHFD2 was broadly regulated by mTORC1 signaling in distinct settings. Insulin increased MTHFD2 mRNA and protein in a rapamycin-sensitive manner in wild-type MEFs ( fig. S3 , B and C), and these were also decreased by rapamycin in primary mouse hepatocytes and various human cancer cell lines ( Fig.  2C and fig. S3D ). MTHFD2 is the most highly overexpressed metabolic enzyme in human cancers (4). Our data suggest that mTORC1, which is frequently activated in cancer (5), might contribute to increased MTHFD2 expression in tumors. In 859 human breast cancer samples (6), elevated mTORC1 signaling, as scored by the abundance of phospho-S6, was associated with increased expression of MTHFD2 and other mTHF cycle genes and, to a lesser extent, enzymes of the serine synthesis pathway. mTORC1 activation did not correlate with expression of cytosolic THF cycle genes ( fig. S3 , E to G).
The cytosolic and mitochondrial THF cycles produce one-carbon formyl groups for various cellular processes, including de novo purine synthesis ( Fig. 2D and fig. S2A ) (7) (8) (9) (10) (11) . To determine whether the mTORC1-mediated induction of MTHFD2 contributes to purine synthesis, we measured the effects of small interfering RNA (siRNA)-mediated depletion of MTHFD2 on flux from 15 N-glutamine into purine intermediates. Indeed, MTHFD2 depletion lowered flux through de novo purine synthesis without affecting mTORC1 signaling (Fig. 2E and fig. S3 , H and I). Formate produced by the mTHF cycle can exit the mitochondria and be converted to the one-carbon donor N 10 -formyl THF in the cytosol (Fig. 2D and fig. S2A ). Tsc2-null cells with activated mTORC1 displayed enhanced incorporation into RNA of radiolabeled carbon from multiple substrates specific for purine synthesis, including (Fig. 2F  and fig. S4A ). These data suggest that MTHFD2 is required for the mTORC1-induced increase in purine synthesis because it increases formate production, with exogenous formate bypassing the need for this enzyme. This is further supported by the fact that MTHFD2 depletion consistently slowed proliferation in Tsc2 −/− MEFs, without substantial effects on cell size, and exogenous formate attenuated this effect (Fig. 2I  and fig. S4 , B and C). MTHFD2 depletion also blocked 14 C-glycine incorporation into RNA in five human cell lines, and, similar to mTORC1 depletion with Raptor siRNAs, loss of MTHFD2 slowed proliferation of these cells ( fig. S4, D and E) .
We also measured effects of candidate transcription factors downstream of mTORC1 (12) (13) (14) (15) on incorporation of 14 C-glycine into RNA and DNA. Of the six transcription factors tested, depletion of the sterol regulatory element binding proteins (SREBP1 and 2), c-Myc, or activating transcription factor 4 (ATF4) specifically attenuated the increase in de novo purine synthesis in Tsc2-deficient cells, without decreasing incorporation of 3 H-adenine (Fig. 3A and fig. S5A ). Of these three transcription factors, only depletion of ATF4 decreased MTHFD2 transcripts and protein in Tsc2-deficient cells (Fig. 3 , B and C) and abolished MTHFD2 protein in wild-type MEFs stimulated with insulin and in human embryonic kidney 293E (HEK293E) cells (fig. S5 , B and C). ATF4 depletion also decreased mRNA for another mTHF gene (Shmt2), as well as genes of the serine synthesis pathway (Psat1 and Psph), with lesser effects on their protein products (Fig.   3C and fig. S5D ) (16, 17) . Consistent with the role of these enzymes in de novo purine synthesis, ATF4 depletion blocked the mTORC1-induced increase in flux from 15 N-glutamine into purine intermediates ( fig. S5E) .
Overexpression of an ATF4 cDNA lacking its 5′-untranslated region increased the abundance of MTHFD2 mRNA and protein and rendered its expression resistant to rapamycin (Fig. 3, D and E), without effects on the cytosolic isoform, MTHFD1 ( fig. S5F) . Alignment of the human, mouse, and rat MTHFD2 promoters revealed a highly conserved, consensus DNA-binding motif for ATF4 (fig. S5G ). Chromatin immunoprecipitation (ChIP) assays demonstrated that ATF4 bound to the MTHFD2 promoter, and ATF4 expression increased Pol II binding to this promoter (Fig. 3F) . As controls, ATF4 bound the promoter of its established target CHOP but not GAPDH. Like loss of MTHFD2, depletion of ATF4 decreased flux from 14 C-glycine into RNA but failed to block incorporation of 14 C-formate (Fig.  3G and fig. S5H ). Thus, MTHFD2 is a transcriptional target of ATF4, and ATF4 promotes de novo purine synthesis, at least in part, through its regulation of formate production by the mTHF cycle. ATF4 DNA-binding elements are overrepresented in the promoters of mTORC1-regulated genes (12) , which suggests that mTORC1 might activate ATF4. Tsc2-deficient cells had increased ATF4 that was lowered by 2 to 4 hours of rapamycin treatment (Fig. 4A) . Loss of TSC2 function in mouse neurons, through conditional deletion of exon 3 (18), activated mTORC1 signaling and increased both ATF4 and its target MTHFD2 in the brain (Fig. 4B) . Treatment of a panel of cancer cell lines, primary mouse hepatocytes, or HEK293E cells with rapamycin for 4 hours or less decreased ATF4 (Fig. 4C and fig. S6, A and B) . The shorterterm effects of mTORC1 inhibition with rapamycin or activation with insulin did not correspond with changes in ATF4 transcripts ( fig. S6 , B and C), but prolonged stimulation or inhibition of mTORC1 caused transcriptional changes ( fig. S6D) (16) . Treatment of cells with the proteasome inhibitor MG132 increased ATF4 but did not affect its regulation by mTORC1 (Fig. 4D) . Therefore, the primary mechanism of regulation of ATF4 by mTORC1 is neither through transcription nor stability, nor does it appear to influence nuclear shuttling of ATF4 ( fig. S6E ). The insulin-stimulated increase in ATF4 was blocked in cells upon inhibition of translation with cycloheximide (Fig. 4E) but was unaffected by inhibition of transcription with actinomycin D (fig. S6F) . Thus, mTORC1 appears to increase ATF4 abundance by promoting its translation.
The translation of ATF4 is well established to be regulated downstream of eukaryotic initiation factor 2a (eIF2a) phosphorylation on Ser 51 in response to cellular stresses, including amino acid deprivation and endoplasmic reticulum (ER) stress (19) (20) (21) . Unlike growth factor-induced ATF4, the up-regulation of ATF4 upon amino acid starvation or exposure to the ER stress-inducing agent tunicamycin was largely resistant to rapamycin (Fig. 4F) . The induction of ATF4 by tunicamycin was abolished in a Ser 51 Ala knock-in mutant of eIF2a (A/A) (21), but the insulin-stimulated, rapamycin-sensitive increase in ATF4 was similar between these cells and their wild-type (S/S) counterparts (Fig. 4G) . These data reveal a regulatory input from mTORC1 to ATF4 that is independent of its established mechanism of regulation by cellular stress.
This study adds purine synthesis to the list of anabolic processes induced by mTORC1 in both normal and cancer cells (1) . In response to growth signals, mTORC1 activates ATF4, which stimulates expression of MTHFD2 and other enzymes of the serine synthesis and mTHF cycle, thereby increasing production of formyl units required for de novo purine synthesis (Fig. 4H) . Purine biosynthetic enzymes organize into dynamic cellular bodies called purinosomes.
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Little is known about the spatiotemporal control of these structures. Using super-resolution microscopy, we demonstrated that purinosomes colocalized with mitochondria, and these results were supported by isolation of purinosome enzymes with mitochondria. Moreover, the number of purinosome-containing cells responded to dysregulation of mitochondrial function and metabolism. To explore the role of intracellular signaling, we performed a kinome screen using a label-free assay and found that mechanistic target of rapamycin (mTOR) influenced purinosome assembly. mTOR inhibition reduced purinosome-mitochondria colocalization and suppressed purinosome formation stimulated by mitochondria dysregulation. Collectively, our data suggest an mTOR-mediated link between purinosomes and mitochondria, and a general means by which mTOR regulates nucleotide metabolism by spatiotemporal control over protein association.
P urine levels in mammalian cells are maintained by the coordinated action of complementary salvage and de novo biosynthetic pathways. Whereas the salvage pathway maintains purine nucleotide levels under normal physiological conditions, the de novo pathway is up-regulated during growth (1, 2) and altered in neoplastic cells (3, 4) . Purinosomes are mesoscale assemblies formed to protect unstable intermediates and increase metabolic flux through the de novo pathway (5-9). These structures are dynamic, form reversibly in response to purine depletion, and act to increase de novo purine biosynthesis (5, 6, 10) . Their formation is cell cycle dependent and can be regulated by G protein-coupled receptor (GPCR) agonists and casein kinase 2 (11) (12) (13) (14) . An increased number of purinosome-containing cells correlates positively with the degree of purine salvage deficiency in Lesch-Nyhan disease (15) . Cellular conditions resulting in disruption of purinosome formation led to enhanced sensitivity to cancer chemotherapeutics (16) . An analogous cellular phenotype was also recently reported for a multifunctional protein involved in pyrimidine biosynthesis (17) . These structures are examples of an increasing number of reported higher-order organizations involving metabolic proteins (7, 18, 19) .
Considering that de novo purine biosynthesis not only provides the nucleotide precursors necessary for mitochondrial adenosine 5′-triphosphate (ATP) production but also conversely demands ATP for its operation, we hypothesized that a synergistic relationship between purinosomes and mitochondria might exist. This synergy would be even more critical in cells that preferentially use oxidative phosphorylation for ATP production, such as several cervical cancers, breast carcinoma, hepatoma, pancreatic cancer, and glioma cell lines (20, 21) . The relationship would also supply onecarbon units generated by the mitochondrial conversion of serine to formate for incorporation into the purine ring during de novo biosynthesis. In this work, we investigated the physical and functional relationship between purinosome and mitochondria using super-resolution imaging, a dynamic mass redistribution assay, and other biochemical measures.
Conventional fluorescence microscopy images initially suggested spatial proximity between purinosomes and mitochondria, but the high density of the mitochondrial network precluded clear demonstration and quantitative characterization of the colocalization between these two structures at diffraction-limited image resolution ( fig. S1 ). To further investigate the spatial distribution of purinosomes, we used threedimensional stochastic optical reconstruction microscopy (3D STORM), a super-resolution fluorescence imaging method (22) (23) (24) , to image HeLa cells under conditions that promote the formation of purinosomes. Purinosomes were imaged via transient transfection of photoactivatable fluorescent protein (mEos2) (25) tagged formylglycinamidine ribonucleotide synthase (FGAMS or PFAS), a core purinosome component (5, 26) . Given the residual dimerization tendency of mEos2, we also tagged FGAMS to recently developed monomeric photoactivatable fluorescent protein, mMaple3 (27) . The number and size distributions of purinosomes were independent of the tagging method ( fig. S2 ).
To investigate purinosome-mitochondria colocalization, we induced purinosome formation by purine starvation, fixed the cells, and immunostained them for a mitochondrial outer membrane translocase (TOM20) using a photoswitchable fluorescent dye (Alexa Fluor 647). Two-color 3D STORM images of cells that exhibited purinosomes revealed spatial colocalization between purinosomes and mitochondria (Fig. 1 ). Under the conditions tested, a substantially larger fraction of purinosomes were colocalized with mitochondria than would be expected if the purinosomes were randomly distributed throughout the cytoplasm (Fig. 1G and fig. S3 ).
To provide further support for the potential physical interactions between purinosomes and mitochondria, we treated cells cultured in purinedepleted conditions with chemical cross-linkers, isolated the mitochondria, and compared the proteins present in these mitochondrial extracts
